The metabolic syndrome: psychopharmacologists should weigh the evidence for weighing the patient.
We are in the midst of a North American epidemic of obesity and type 2 diabetes. Since patients with psychiatric disorders who receive psychopharmacologic treatments may be at even greater risk than the general population for weight gain, dyslipidemia, and diabetes and their complications, psychopharmacologists now need standards for how to monitor and manage these risks.
Stahl
Stephen M
SM
Neuroscience Education Institute in Carlsbad, Calif 92009, USA.
D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology*; D006801:Humans; D006946:Hyperinsulinism / Q000209:etiology; D006949:Hyperlipidemias / Q000209:etiology; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000150:complications*; D009765:Obesity / Q000209:etiology*; D011600:Psychopharmacology / Q000379:methods*; D011619:Psychotropic Drugs / Q000009:adverse effects*
D011619:Psychotropic Drugs